Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.
Brad S. Kahl(UW Health University Hospital), Bruce D. Cheson(Center for Cancer and Blood Disorders), John P. Leonard(New York University), Nancy L. Bartlett(Washington University in St. Louis), Michael E. Williams(University of Virginia), Richard H. van der Jagt(Ottawa Hospital), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Kristen N. Ganjoo(Stanford Medicine), Katherine Robinson(Queen Elizabeth II Health Sciences Centre), Robin Joyce(Beth Israel Deaconess Medical Center)
Cited by 15
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k